Glaxo Wellcome Inc.

Burroughs Wellcome Co.

Smithkline Beecham Corporation

Saad George Rahim

Thomas Spector

David J T Porter

Thomas A Krenitsky

David J Porter

Dorothy J Purifoy

John W Selway

Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted Calkyl, Calkenyl, 1-halo-Calkenyl and halo-substituted Calkynyl.

Uracil reductase inactivators

This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.

Pharmaceutical compositions of 5-alkynyl uracil compounds

Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, iodo, cyano, halo-substituted C,alkyl, C,alkenyl, 1-halo-C,alkenyl and halo-substituted C,aklynyl.

Uracil reductase inactivatores

The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularly useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil.

This application relates to pharmaceutical compositions of 5-alkynyl-dideoxyridbouracils which generates 5-alkynyluracils in vivo, which are inactivators of uracil reductase.

Pharmaceutical compositions of 5-alkynyl-dideoxyribouracil

This invention relates to pharmaceutical compositions of 5-alkynuracil.

The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).

Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.

Pharmaceutical compositions of 5-substituted uracil compounds

The present invention relates to a 3'-substituted pyrimidine nucleoside and its use in medical therapy, particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations.

5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine

2',3'-dideoxy-3'-fluoro-5-ethyngluridine

The present invention relates to certain novel 5-substituted pyrimidine nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of varicella zoster virus, cytomegalovirus and Epstein Barr virus infections. Also provided are pharmaceutical formulations and processes for the preparation of the compounds according to the invention.

Antiviral compounds

The invention is a method for using 1-(.beta.-D-arabinofuranosyl)-5-propynyluracil or its salts as the active ingredient in pharmaceutical compositions in the treatment of varicella zoster viral infections whether expressed as chicken pox or shingles.

1-(.beta.-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV

The present invention relates to the use of 2'-deoxy-5-ethynyluridine and its pharmaceutically acceptable derivatives in the treatment and prophylaxis of varicella zoster virus and cytomegalovirus infections. Also provided are pharmaceutical formulations and processes for the preparation of the compounds according to the invention.

Growing community of inventors

Beckenham, United Kingdom

Saad George Rahim